Financial Performance - The total revenue for the year ended December 31, 2025, was HKD 68,356,000, representing a 80.8% increase from HKD 37,792,000 in 2024[4] - Gross profit for 2025 was HKD 14,183,000, slightly up from HKD 13,940,000 in 2024, indicating a stable gross margin[4] - The net profit attributable to the owners of the company for 2025 was HKD 59,117,000, a significant recovery from a loss of HKD 1,233,000 in 2024[5] - Basic and diluted earnings per share for 2025 were HKD 6.11, compared to a loss of HKD 0.13 per share in 2024[5] - The reported segment profit for the fiscal year 2025 was HKD 67,142,000, compared to HKD 8,122,000 in 2024, indicating a substantial increase in profitability[19] - Other income recorded a gain of HKD 50,200,000, a turnaround from a loss of HKD 1,600,000 in the previous year, primarily due to securities investment[32] Assets and Liabilities - Total assets increased to HKD 227,893,000 in 2025 from HKD 159,330,000 in 2024, reflecting a growth of 42.9%[6] - Current liabilities increased to HKD 87,756,000 in 2025 from HKD 68,302,000 in 2024, showing a rise of 28.6%[6] - The total liabilities rose to HKD 108,656,000 in 2025, compared to HKD 99,202,000 in 2024, indicating a 9.7% increase[19] - The company's equity total reached HKD 119,237,000 in 2025, up from HKD 60,128,000 in 2024, marking a 98.2% increase[6] Inventory and Financial Assets - Inventory rose to HKD 23,408,000 in 2025, up from HKD 11,409,000 in 2024, indicating increased stock levels[6] - The company reported a significant increase in financial assets, with held-for-trading investments rising to HKD 109,024,000 from HKD 59,373,000[6] - The company reported a net impairment loss of HKD (10,621,000) for the fiscal year 2025, compared to HKD (1,300,000) in 2024, highlighting an increase in credit loss provisions[26] Revenue Breakdown - The medical products segment generated revenue of HKD 57,694,000 in 2025, up from HKD 25,566,000 in 2024, reflecting a growth of 125.8%[22] - As of December 31, 2025, the revenue breakdown by product category includes: blood collection devices and equipment at HKD 11,408, custom components for medical devices at HKD 20,467, and surgical instruments, orthopedic tools, imaging equipment, and sterilization products at HKD 25,819[47] Market and Strategic Initiatives - The company plans to expand its product portfolio to include more categories of medical equipment, enhancing sales growth[35] - The company aims to maintain long-term competitive advantages through streamlined processes and effective resource utilization[35] - The company plans to invest in advanced manufacturing technologies, such as 3D printing, to meet medical-grade standards and enhance precision manufacturing[42] - The company aims to leverage its industry knowledge and existing commercial channels to enhance sales of newly licensed products and strengthen its medical business segment[44] Operational and Production Capacity - The maximum annual production capacity of the company's facility in Dongguan, China, is approximately 5,000,000 units[58] - The company employs 15 full-time staff to operate the factory and may hire part-time workers based on customer orders[61] - The company has fully depreciated its factory and machinery since most have exceeded their estimated useful life of 5 to 10 years[58] Investment and Financial Management - The group recorded a realized and unrealized gain of HKD 50.1 million from trading investments for the year ending December 31, 2025, compared to a loss of HKD 1.8 million in 2024[74] - The investment strategy aims to maximize sustainable long-term returns while maintaining a diversified portfolio to minimize potential financial risks[78] - The company has no borrowings from financial institutions as of December 31, 2025[90] Corporate Governance and Compliance - The company has complied with the corporate governance code as per the Hong Kong Stock Exchange rules throughout the year[99] - The audit committee consists of three independent non-executive directors, ensuring oversight of financial reporting and internal controls[102] Future Outlook - The company aims to optimize its diversified business portfolio, focusing on high-value growth opportunities in the medical device sector[88] - The company plans to expand its customer base targeting hospital clients, which are expected to provide stable and high-potential revenue sources[62] - The company will implement a data-driven regional expansion strategy to optimize service delivery quality and strengthen commitments to hospital clients[63]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 1 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 （於百慕達註冊成立之有限公司） （股份代號：630） 正面盈利預告 本公告乃雋泰控股有限公司（「本公司」）根據香港聯合交易所有限公司證券上市 規則（「上市規則」）第13.09條及香港法例第571章《證券及期貨條例》（「證券及期 貨條例」）第XIVA部內幕消息（如上市規則所定義）之條文而作出。 本公司之董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，預期 本集團將就截至二零二五年十二月三十一日止年度錄得盈利約59百萬港元，對比 截至二零二四年十二月三十一日止年度則錄得虧損約1百萬港元。該盈利主要由於(i) 收益由截至二零二四年十二月三十一日止年度約38百萬港元增加至截至二零二五 年十二月三十一日止年度約68百萬港元，此乃由於本集團於年內拓展產品組合， 涵蓋更廣泛的醫療設備，(ii)按公平值計入損益之金融資產之公平值收益約 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 董事會召開日期 雋泰控股有限公司（「本公司」）董事會（「董事會」）謹此公佈，本公司訂於二零 二六年三月三十日（星期一）舉行董事會會議，以（其中包括）批准本公司及其附 屬公司截至二零二五年十二月三十一日止之年度業績公佈，及考慮宣派末期股息（如 有）。 承董事會命 雋泰控股有限公司 主席 賈明暉 於本公告日期，執行董事為張亨鑫先生及賈明暉先生；而獨立非執行董事為李斯 斯女士、歐陽銘賢先生及郭鎮輝先生。 香港，二零二六年三月十二日 * 僅供識別 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00630 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | 本月底法定/註冊股本總額： HKD 400,000,000 FF301 第 1 頁 共 10 頁 v 1.2.0 ...

公司名稱: AMCO United Holding Limited 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00630 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | 本月底法定/註冊股本總額： HKD 400,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月 ...

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 公司名稱: AMCO United Holding Limited 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00630 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.05 HKD | | 400,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.05 HKD | | 400,000,000 | 本月 ...

Revenue Performance - Medical products revenue for the fiscal year 2024 reached HKD 25.57 million, a 16.5% increase from HKD 21.94 million in fiscal year 2023[5] - Custom components for medical equipment saw a significant revenue increase of 86%, driven by a shift towards comprehensive systems like Continuous Glucose Monitoring (CGM)[8] - Sales of blood collection tubes and equipment dropped from HKD 30.43 million in fiscal year 2022 to HKD 14.13 million in fiscal year 2023, a decline of 53.6%[7] - Revenue from pandemic-related products fell to zero in fiscal year 2023, a 100% decrease from HKD 16.34 million in fiscal year 2022, due to normalized demand post-COVID-19[6] Product Development and Expansion - The company plans to expand its product offerings to include surgical instruments, orthopedic tools, imaging equipment, and disinfection products[11] - The company intends to launch 2 to 3 new co-developed products by 2026, including surgical instrument kits and imaging equipment accessories[14] - The newly obtained production license is a strategic expansion of the existing medical business segment, significantly broadening the product portfolio with new devices and components, including infusion and transfusion devices, nursing and care equipment, and protective gear[15] - The production license allows the company to market and sell a diverse range of medical devices in China, covering categories such as active and passive surgical instruments, orthopedic surgical instruments, medical imaging equipment, and more[16] Regulatory Compliance and Quality Control - The company is focusing on diversifying its product lines while ensuring regulatory compliance with certifications like CE and FDA[11] - The company emphasizes compliance with strict quality and regulatory standards to ensure the highest levels of safety and effectiveness for its medical products[28] - The production facilities have received FDA certification, reflecting the company's commitment to adhering to strict regulatory frameworks[28] - The company emphasizes strict quality control and regulatory compliance in all operations, whether internal or outsourced[30] Market Strategy and Partnerships - The company aims to achieve product registration and distribution permits in Shandong by August 2025, marking a significant milestone for market entry[12] - The company is actively seeking partnerships with subcontractors that have existing certifications to expedite market entry without significant capital expenditure[12] - The company anticipates obtaining additional provincial registrations in China by the fourth quarter of 2026 to expand its geographical coverage[13] - The company will adopt a data-driven regional expansion strategy to optimize service delivery and enhance commitment to hospital clients[34] Operational Capacity and Team - The company has established an 8-member dedicated operations team led by Mr. Dai Zhongliang, who has over ten years of experience in the medical products industry, to manage and monitor all manufacturing processes[27] - The company has a maximum annual production capacity of approximately 5 million units at its existing facility in Dongguan, China[31] - The business model under the production license remains unchanged, ensuring rapid expansion of the product range while maintaining effective operational strategies[17] Financial Projections and Market Outlook - The Chinese healthcare market is projected to grow at a compound annual growth rate of approximately 12-14%, reaching over $250 billion by 2030[32] - The company plans to achieve estimated sales of RMB 20 million by December 2025 through strategic partnerships with clients introduced by a new management team member[33] - The board is optimistic about business prospects due to strong market demand and strategic initiatives taken[32] - The establishment of a new subsidiary in Jinan, Shandong, aims to strengthen the company's market presence in China[33] Customer Engagement and Sales Strategy - The sales and marketing department is tasked with customer engagement, handling inquiries, and coordinating sales orders to ensure timely processing and delivery[23] - The company aims to enhance its core business by providing a more comprehensive product suite to meet broader customer needs and generate additional revenue streams[15] - The company will expand its customer base to include hospital clients, diversifying revenue sources and strengthening market position[33]

致：香港交易及結算所有限公司 公司名稱: AMCO United Holding Limited 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00630 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | | | | 本月底 ...

Core Viewpoint - JunTai Holdings (00630.HK) announced the appointment of Li Sisi as an independent non-executive director, effective from November 14, 2025, along with his membership in the audit committee, nomination committee, and remuneration committee [1] Group 1 - JunTai Holdings has made a significant governance change by appointing Li Sisi to its board [1] - The appointment includes roles in key committees, indicating a strategic move towards enhancing corporate governance [1] - The effective date of the appointment is set for November 14, 2025, allowing for a transition period [1]

Group 1 - The company, JunTai Holdings (00630), announced the appointment of Ms. Li Sisi as an independent non-executive director effective from November 14, 2025 [1] - Ms. Li will also serve as a member of the Audit Committee, Nomination Committee, and Remuneration Committee under the board [1]